{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:47:37Z","timestamp":1792205257350,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["02.709 TTU-TB ClinTB"],"award-info":[{"award-number":["02.709 TTU-TB ClinTB"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020483","name":"Insmed","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cmi.2023.02.013","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T22:38:15Z","timestamp":1677278295000},"page":"751-757","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Long-term treatment outcomes in patients with multidrug-resistant tuberculosis"],"prefix":"10.1016","volume":"29","author":[{"given":"Christina","family":"Maier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru","family":"Chesov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Schaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kalsdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6nke","family":"Andres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Friesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.02.013_bib1","series-title":"Global tuberculosis report 2022","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.cmi.2023.02.013_bib2","series-title":"The End TB strategy","author":"World Health Organization","year":"2014"},{"key":"10.1016\/j.cmi.2023.02.013_bib3","volume":"2011","author":"World Health Organization","year":"2011","journal-title":"Global tuberculosis report"},{"key":"10.1016\/j.cmi.2023.02.013_bib4","series-title":"Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.cmi.2023.02.013_bib5","series-title":"Bericht zur epidemiologie der tuberkulose in Deutschland fur 2020","author":"Robert-Koch-Institut","year":"2021"},{"key":"10.1016\/j.cmi.2023.02.013_bib6","series-title":"Definitions and reporting framework for tuberculosis \u2013 2013 revision","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.cmi.2023.02.013_bib7","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMc1603274","article-title":"Treatment outcomes in multidrug-resistant tuberculosis","volume":"375","author":"G\u00fcnther","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.02.013_bib8","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1164\/rccm.202009-3527OC","article-title":"Evidence-based definition for extensively drug-resistant tuberculosis","volume":"204","author":"Roelens","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2023.02.013_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00765-2022","article-title":"Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany","volume":"60","author":"Otto-Knapp","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2023.02.013_bib10","first-page":"408","article-title":"Case definition for extensively drug-resistant tuberculosis","volume":"81","author":"World Health Organization","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.cmi.2023.02.013_bib11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2023.02.013_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cmi.2022.07.026","article-title":"Availability and costs of medicines for the treatment of tuberculosis in Europe","volume":"29","author":"G\u00fcnther","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2023.02.013_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1473-3099(18)30004-5","article-title":"A\u00a0cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study","volume":"18","author":"Walker","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.02.013_bib14","doi-asserted-by":"crossref","first-page":"610","DOI":"10.5588\/ijtld.16.0917","article-title":"An overview of tuberculosis and migration","volume":"21","author":"Dhavan","year":"2017","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2023.02.013_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijid.2016.12.025","article-title":"Tackling TB in low-incidence countries: improving diagnosis and management in vulnerable populations","volume":"56","author":"Heuvelings","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2023.02.013_bib16","series-title":"Asylum seekers benefits act (asylbewerberleistungsgesetzt) 1993 (revision 2022)","author":"Ministry of Justice of Germany","year":"2022"},{"key":"10.1016\/j.cmi.2023.02.013_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00804-2021","article-title":"World Health Organization treatment outcome definitions for tuberculosis: 2021 update","volume":"58","author":"Linh","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2023.02.013_bib18","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.12.2100183","article-title":"Recurrent tuberculosis in The Netherlands \u2013 a 24-year follow-up study, 1993 to 2016","volume":"27","author":"Erkens","year":"2022","journal-title":"Euro Surveill"},{"key":"10.1016\/j.cmi.2023.02.013_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijid.2021.07.067","article-title":"Long-term survival of treated tuberculosis patients in comparison to a general population in South India: a matched cohort study","volume":"110","author":"Selvaraju","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2023.02.013_bib20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0140-6736(20)31316-7","article-title":"Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis","volume":"396","author":"Bisson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2023.02.013_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1164\/rccm.201710-2141OC","article-title":"Clinical management of multidrug-resistant tuberculosis in 16 European Countries","volume":"198","author":"G\u00fcnther","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2023.02.013_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.5588\/ijtld.21.0036","article-title":"Therapeutic strategies and outcomes of multidrug-resistant and pre-extensively drug-resistant tuberculosis in Italy: a nationwide study","volume":"25","author":"Riccardi","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2023.02.013_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-020-09360-7","article-title":"Risk factors affecting treatment outcomes for pulmonary tuberculosis in Finland 2007-2014: a national cohort study","volume":"20","author":"Korhonen","year":"2020","journal-title":"BMC Public Health"},{"key":"10.1016\/j.cmi.2023.02.013_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-019-0561-z","article-title":"Treatment outcomes of drug-resistant tuberculosis in The Netherlands, 2005-2015","volume":"8","author":"Pradipta","year":"2019","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.cmi.2023.02.013_bib25","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01467-2019","article-title":"Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis","volume":"55","author":"Abidi","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2023.02.013_bib26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.02.013_bib27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.02.013_bib28","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:24:00Z","timestamp":1778592240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1198743X23000836"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.02.013","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term treatment outcomes in patients with multidrug-resistant tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.02.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}